Morphine-6-glucuronide

Morphine-6-glucuronide (M6G) is a major metabolite of morphine, a potent opioid analgesic. It is formed in the body by the glucuronidation of morphine, a process mediated by the enzyme UDP-glucuronosyltransferase (UGT).

Pharmacology

M6G has been found to have analgesic potency several times greater than that of morphine. This is due to its higher affinity for the mu opioid receptor, the primary target of opioid analgesics. M6G also has a longer half-life than morphine, which contributes to its prolonged analgesic effect.

Clinical significance

The clinical significance of M6G lies in its potential to cause opioid toxicity in patients with impaired renal function. This is because M6G is primarily excreted by the kidneys, and its accumulation in the body can lead to adverse effects such as respiratory depression and sedation.

Therapeutic use

M6G has been investigated for its potential use as a therapeutic agent in its own right. Studies have suggested that it may provide effective pain relief with fewer side effects than morphine. However, further research is needed to confirm these findings and to determine the optimal dosing regimen for M6G.

See also

• Morphine
• Glucuronidation
• Opioid toxicity

References

‎